Home Cart Sign in  
Chemical Structure| 912445-05-7 Chemical Structure| 912445-05-7

Structure of Veliparib 2HCl
CAS No.: 912445-05-7

Chemical Structure| 912445-05-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2, with Ki values of 5.2 nM and 2.9 nM in cell-free assays, respectively.

Synonyms: ABT-888 dihydrochloride; ABT-888 (hydrochloride); Veliparib

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Veliparib 2HCl

CAS No. :912445-05-7
Formula : C13H18Cl2N4O
M.W : 317.21
SMILES Code : O=C(C1=C2NC([C@]3(C)NCCC3)=NC2=CC=C1)N.[H]Cl.[H]Cl
Synonyms :
ABT-888 dihydrochloride; ABT-888 (hydrochloride); Veliparib
MDL No. :MFCD12407402

Safety of Veliparib 2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Veliparib 2HCl

epigenetics
DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
DU145, SF295 10 μM 72 h The cytotoxicity of three clinically relevant PARP inhibitors shows marked differences across different cell lines with MK-4827 and olaparib being the most cytotoxic and veliparib the least. PMC3528345
Human liver lysosome lysate 0.5 μM 30 min, 2 h, 24 h To investigate the rate of release of veliparib and its correlation with the chemical nature of the prodrugs. PMC10184315
D425GiL medulloblastoma cells up to 25 µM 72 hours To determine the effect of Veliparib on medulloblastoma cell viability, results showed minimal effect on cell viability at concentrations up to 25 µM. PMC8116896
D425GiL medulloblastoma cells 10 µM 10, 20, 40, 60, 80, 100, or 120 minutes To assess the effect of Veliparib on the repair of radiation-induced DNA damage using the alkaline comet assay, results showed that Veliparib significantly delayed DNA damage repair. PMC8116896
D425 medulloblastoma cells 10 µM 24 hours To assess the effect of Veliparib on the number of γH2AX and RPA32/RPA2 foci, results showed that Veliparib significantly increased the number of γH2AX foci, indicating increased DNA damage. PMC8116896
D283Luc2 medulloblastoma cells 10 µM 14 days To assess the effect of Veliparib on the colony-forming capacity of medulloblastoma cells using clonogenicity assays, results showed that Veliparib significantly impaired colony-forming capacity. PMC8116896
LNCaP cells 0-50 µM 3 days To evaluate the sensitivity of PCa cells to Veliparib, results showed that Veliparib had no noticeable toxicity in all tested cells at concentrations under 50 µM. PMC6048811
DU145 cells 0-50 µM 3 days To evaluate the sensitivity of PCa cells to Veliparib, results showed that DU145 cells were more sensitive to Veliparib. PMC6048811
primary mouse cortical neurons 1 μM 14 days prevented the α-syn PFF-mediated PARP activation and cell death PMC6431793
CAPAN-1 cells 1, 10, 25 μM Chromatin fractionation assays showed that UKTT15 exhibited an increased ability to trap PARP-1 on DNA compared to veliparib in MMS-treated CAPAN-1 cells. PMC7347020

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD/Rag1−/− mice D425GiL medulloblastoma xenograft model Oral 12.5 mg/kg twice daily for 9 days To assess the effect of Veliparib combined with radiotherapy in a medulloblastoma mouse model, results showed that combination therapy significantly increased survival. PMC8116896
Nude mice DU145 xenograft model Oral gavage 25 mg/kg/day Once daily for 3 weeks To validate the antitumor effect of Veliparib combined with SAHA, results showed that the combination therapy significantly inhibited the growth of xenografts. PMC6048811
Mice α-syn PFF injection model Oral 125 mg/kg continuous administration reduced α-syn PFF-induced DA neuron loss PMC6431793

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01123876 Gastric Cancer PHASE1 COMPLETED 2025-01-15 Site Reference ID/Investigator... More >># 24987, Scottsdale, Arizona, 85258, United States|Site Reference ID/Investigator# 24985, Los Angeles, California, 90033, United States|Site Reference ID/Investigator# 26742, Los Angeles, California, 90033, United States|Site Reference ID/Investigator# 24986, Washington, District of Columbia, 20007, United States|Site Reference ID/Investigator# 24922, Durham, North Carolina, 27710, United States|Site Reference ID/Investigator# 24983, Nashville, Tennessee, 37232-6868, United States|Site Reference ID/Investigator# 75713, Seoul, 138-736, Korea, Republic of|Site Reference ID/Investigator# 75714, Seoul, Korea, Republic of Less <<
NCT01472783 Recurrent, Epithelial Ovarian ... More >>Cancer Less << PHASE1|PHASE2 COMPLETED 2025-08-16 Department of Oncology, Vejle ... More >>Hospital, Vejle, 7100, Denmark Less <<
NCT01853306 Oncology|BRCA Mutated|High Gra... More >>de Serous Ovarian Cancer|BRCA Mutated Breast Cancer Less << PHASE1 COMPLETED 2017-06-29 -
NCT03123211 Solid Tumors With Documented B... More >>RCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound|Triple Negative Breast Cancer (TNBC)|High Grade Serous Ovarian Cancer|Patients Requiring Veliparib Suspension Formulation Less << NO_LONGER_AVAILABLE - -
NCT03044795 Cancer PHASE2 WITHDRAWN 2025-11-20 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.15mL

0.63mL

0.32mL

15.76mL

3.15mL

1.58mL

31.52mL

6.30mL

3.15mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories